DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for intellectual disability, X-linked 99 — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleIntellectual disability, X-linked 99 maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
approvedMelatoninMelatonin receptor agonist
Structures already discussed alongside intellectual disability, x-linked 99 in the retrieved literature, rendered from public PubChem SMILES. Which drugs appear here reflects the evidence found, not a ranked prediction.
Molecular view
Crystal structure of fad quinone reductase 2 — Melatonin has a real, experimentally solved structure in complex with this target (PDB 4QOG, 1.4 Å). This is the drug's own deposited structure, not a prediction, and confirms it is a structurally characterised molecule rather than an untested guess.
Loading structure…
helix sheet ml1drag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 4QOG · 1.4 Å · ligand Melatonin (ML1). Experimental structure, not a prediction.
What the evidence adds up to
A 2022 study identified a truncating variant in the USP9X gene, c.885_889delAAAAG, p.(Lys296Serfs*4), in two non-twin sisters with syndromic intellectual disability (MRX99F). The variant showed incomplete penetrance. X-inactivation, RNA-Seq, and full quad exome analyses failed to find a modifier explaining the reduced penetrance. The authors note that while penetrance of pathogenic USP9X variants in females appears high (95%) and variants are often de novo, incomplete penetrance should be considered.
A 2014 retrospective case note analysis of 119 patients with intellectual disability prescribed melatonin for sleep disturbance found that 88 (73.9%) had documented improvements in sleep pattern. Patients with autism spectrum disorder or autistic traits were more likely to respond than those without (P = 0.0229). No serious short-term adverse effects were reported; some patients lost initial efficacy and responded to a higher dose. The authors call for large-scale studies on long-term side effects and optimal dosing.
A 2018 industry review of targeted treatments for fragile X syndrome (FXS), a leading monogenic cause of intellectual disability, notes that several mechanism-based agents have entered clinical trials. The review identifies challenges in trial design and calls for future improvements but provides no new efficacy data from those trials.
What is still missing: for USP9X-related intellectual disability, no targeted therapy is described and the mechanism of incomplete penetrance remains unexplained. For sleep disturbance in intellectual disability, large-scale, long-term safety and dosing studies for melatonin are lacking. For fragile X syndrome, no new trial results are reported in these abstracts, and the review does not specify which agents succeeded or failed.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Brain Sciences · 2018 · 33 citations · open access
Clinical Development of Targeted Fragile X Syndrome Treatments: An Industry Perspective
Abstract) gene, resulting in a deficit of fragile X mental retardation protein (FMRP). The clinical presentation of FXS is variable, and is typically associated with developmental delays, intellectual disability, a wide range of behavioral issues, and certain identifying physical features. Over the past 25 years, researchers have worked to understand the complex relationship between FMRP deficiency and the symptoms of FXS and, in the process, have identified several potential targeted therapeutics, some of which have been tested in clinical trials. Whereas most of the basic research to date has been led by experts at academic institutions, the pharmaceutical industry is becoming increasingly involved with not only the scientific community, but also with patient advocacy organizations, as more promising pharmacological agents are moving into the clinical stages of development. The objective of this review is to provide an industry perspective on the ongoing development of mechanism-based treatments for FXS, including identification of challenges and recommendations for future clinical trials.
International Journal of Developmental Disabilities · 2014 · 10 citations
Use of melatonin for sleep disturbance in a large intellectual disability psychiatry service
AbstractAims and methods:A retrospective case note analysis was undertaken to evaluate prescribing practices, tolerability and perceived effectiveness in patients treated with melatonin for sleep disturbance in a psychiatry service caring for people with intellectual disability in a city with a population of 1·1 million.Two authors scrutinized notes to extract information on to a previously agreed proforma on degree of intellectual disability, comorbid conditions and medication, type of sleep disturbance, dose of melatonin, response to treatment and side effects.Results:One hundred and nineteen patients of whom 103(86·5%) had Autism Spectrum Disorder or traits, had been prescribed melatonin; Eighty eight (73·9%) of these had documented improvements in their sleep pattern. There was variation in prescribing practice regarding doses used and titration regime. No serious adverse effects were associated with its use in the short term; those which did occur probably do not represent a rise above events that would be seen by chance in this population. Patients with autistic spectrum disorder (ASD) or autistic traits were more likely to show a positive response to melatonin than those with learning disability and no ASD/autistic traits (P = 0·0229.). Some subjects showed a loss of efficacy after initial response, some of who responded to a higher dose.Clinical implications:Melatonin appears to represent an effective treatment for sleep disorders in children and adults with intellectual disability (ID), patients with ASD are likely to be responders. It is associated with few serious side effects. There is a need for large-scale studies to further evaluate short and long-term side effects and to determine optimal dosing regimes.
American Journal of Medical Genetics Part A · 2022 · 4 citations
Exome and <scp>RNA‐Seq</scp> analyses of an incomplete penetrance variant in <scp><i>USP9X</i></scp> in female‐specific syndromic intellectual disability
AbstractPathogenic variants in USP9X, on X chromosome, have been implicated in syndromic intellectual disability (ID) in both males and females with distinct craniofacial features. We report a truncating variant, c.885_889delAAAAG, p.(Lys296Serfs*4), in the USP9X gene with incomplete penetrance in two nontwin female siblings with phenotypic resemblance to female-specific syndromic ID (MIM 300969, also known as MRX99F). To investigate the possible genetic etiology of the reduced penetrance, X-inactivation, RNA-Seq, and full quad exome analyses were attempted, but failed to identify a promising candidate modifier. While the penetrance of pathogenic variants in USP9X in female appears to be high (95%) and the variants frequently occur de novo, incomplete penetrance should be considered.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
